Enter a phrase above to search files and articles within the site.

Typically materials that are more than 5 years old will be archived
Displaying 1 - 20 of 1116 results

The Future Directions of Lupus Research


The Future Directions of Lupus Research is a planning document presented by the National Institutes of Health (NIH) and developed with tremendous input from scientific experts from the lupus research community and beyond. This document focuses on five major areas of research including: disease etiology; innate immunity, acquired immunity and inflammation; target organ damage; pediatric lupus, special populations and health services research; and diagnosis and treatment.

NIH American Indian / Alaska Native Health Communications and Information Work Group


Formed in 2005, the NIH AI/AN Health Communications and Information Work Group provides a forum for health education and communications staff from National Institutes of Health (NIH) Institutes, Centers, and Offices to share strategies and effective communication approaches to develop and disseminate health information to American Indian and Alaska Native



What is acne? Acne is a common skin condition that happens when hair follicles under the skin become clogged. Oil and dead skin cells plug the pores, and outbreaks of lesions (often called pimples or zits) can happen. Most often, the outbreaks occur on the face but can also appear on the back, chest, and shoulders. For most people, acne tends to go away by the time they reach their thirties, but some people in their forties and fifties continue to have this skin problem.

Social Media Moderation Policy


NIAMS reserves the right to monitor all postings to its social media pages. Individuals commenting in their official capacity on any platform must identify their Agency relationship. Comments that contain the following will be deleted: Political endorsements of parties, candidates, or groups. Commercial endorsements of products, services, organizations, or other

Freedom of Information Act (FOIA)


The FOIA, 5 U.S.C. 552, provides individuals with a right to access to records in the possession of the Federal government. The government may withhold information pursuant to the nine exemptions and three exclusions contained in the Act. If you have questions regarding FOIA requests pending with the National Institute

Privacy Statement


Protecting your privacy is very important to us. Once you leave the niams.nih.gov site, you are subject to the privacy policy for the site(s) you are visiting. We do not collect any personally identifiable information (PII) about you during your visit to the NIAMS website unless you choose to provide

Accessibility Statement


The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health (NIH) is making every effort to ensure that the information available on our website is accessible to all. If you use special adaptive equipment to access the Web and encounter problems when using



Information on this site The text you find on this site is in the public domain. You may use and reproduce text material you find on this website. Many of the photographs appearing on this website have been purchased from other sources and are copyrighted. The NIAMS cannot grant anyone

NIAMS Clinical Trial Planning Grants (R34)


The NIAMS has determined that investigator-initiated, interventional clinical trials requesting NIAMS support should undergo a rigorous planning, design, and documentation phase before a decision is made to implement a study with a substantial fiscal and human resource investment. The implementation of a clinical trial requires extensive administrative planning (e.g., protocol

NIAMS Clinical Trial Implementation Cooperative Agreement (U01)


Following the completion of designated milestones in the clinical trial planning process, investigators may consider applying for a Clinical Trial Implementation Cooperative Agreement (U01). The NIAMS will only accept, peer review, and consider funding applications for implementation of investigator-initiated clinical trials when the necessary planning and administrative tasks have been